New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
Acute on chronic liver failure
Ascites
Cirrhosis
Hepatic encephalopathy
Infection
Inflammation
Varices
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
22
10
2020
revised:
08
01
2021
accepted:
11
01
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
8
2
2022
Statut:
ppublish
Résumé
Traditionally, the complications of cirrhosis, namely variceal bleeding, ascites and hepatic encephalopathy, were thought to result predominantly from circulatory dysfunction and altered organ perfusion arising as a result of portal hypertension. Over the past 20 years, large, international prospective studies have indicated the importance of systemic inflammation and organ immunopathology as additional determinants of organ dysfunction in cirrhosis, which not only manifests in the liver, brain, circulation and the kidneys, but also the immune system, gut, muscles, adrenal glands, reproductive organs, heart and lungs. This review provides an overview of the traditional and emerging concepts around the initiation and maintenance of organ dysfunction in cirrhosis and proposes a new paradigm based upon a better understanding of acute decompensation of cirrhosis. The interaction between the traditional concepts and the emerging perspectives remains a matter of great interest and the basis for future research.
Identifiants
pubmed: 34039485
pii: S0168-8278(21)00029-5
doi: 10.1016/j.jhep.2021.01.018
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S14-S26Informations de copyright
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest Dr. Jalan has research collaborations with Yaqrit and Takeda. Dr. Jalan is the inventor of OPA, which has been patented by UCL and licensed to Mallinckrodt Pharma. He is also the founder of Yaqrit limited, a spin out company from University College London. The remaining authors disclose no conflicts. Please refer to the accompanying ICMJE disclosure forms for further details.